JP2020532508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532508A5 JP2020532508A5 JP2020511399A JP2020511399A JP2020532508A5 JP 2020532508 A5 JP2020532508 A5 JP 2020532508A5 JP 2020511399 A JP2020511399 A JP 2020511399A JP 2020511399 A JP2020511399 A JP 2020511399A JP 2020532508 A5 JP2020532508 A5 JP 2020532508A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- syndrome
- encephalopathy
- bipyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- -1 (4-benzyl-4-hydroxypiperidine-1-yl) (2,4'-bipyridine-3-yl) Chemical group 0.000 claims 14
- 208000014644 Brain disease Diseases 0.000 claims 10
- 208000032274 Encephalopathy Diseases 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 8
- 230000001037 epileptic effect Effects 0.000 claims 7
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 6
- 229960002036 phenytoin Drugs 0.000 claims 6
- 206010010904 Convulsion Diseases 0.000 claims 5
- XKUZMIUSBMCVPP-UHFFFAOYSA-N soticlestat Chemical compound C1CN(C(=O)C=2C(=NC=CC=2)C=2C=CN=CC=2)CCC1(O)CC1=CC=CC=C1 XKUZMIUSBMCVPP-UHFFFAOYSA-N 0.000 claims 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- 239000001961 anticonvulsive agent Substances 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 claims 3
- 101710178912 Cyclin-dependent kinase-like 5 Proteins 0.000 claims 3
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims 3
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- LTYDTBHSPIJPEG-UHFFFAOYSA-N 3-methyl-5,5-diphenylimidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 LTYDTBHSPIJPEG-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 claims 2
- 101000923091 Danio rerio Aristaless-related homeobox protein Proteins 0.000 claims 2
- 201000007547 Dravet syndrome Diseases 0.000 claims 2
- 101710150822 G protein-regulated inducer of neurite outgrowth 1 Proteins 0.000 claims 2
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 claims 2
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims 2
- 102100031470 Homeobox protein ARX Human genes 0.000 claims 2
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 claims 2
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 claims 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims 2
- 101000923090 Homo sapiens Homeobox protein ARX Proteins 0.000 claims 2
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 claims 2
- 101000994626 Homo sapiens Potassium voltage-gated channel subfamily A member 1 Proteins 0.000 claims 2
- 101000994632 Homo sapiens Potassium voltage-gated channel subfamily A member 2 Proteins 0.000 claims 2
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 claims 2
- 101001072243 Homo sapiens Protocadherin-19 Proteins 0.000 claims 2
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims 2
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims 2
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims 2
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 claims 2
- 102100034368 Potassium voltage-gated channel subfamily A member 1 Human genes 0.000 claims 2
- 102100034369 Potassium voltage-gated channel subfamily A member 2 Human genes 0.000 claims 2
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims 2
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 claims 2
- 102100036389 Protocadherin-19 Human genes 0.000 claims 2
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims 2
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims 2
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims 2
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims 2
- 229960000571 acetazolamide Drugs 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 2
- 229960003529 diazepam Drugs 0.000 claims 2
- GQPXYJNXTAFDLT-UHFFFAOYSA-L disodium;(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate Chemical compound [Na+].[Na+].O=C1N(COP([O-])(=O)[O-])C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 GQPXYJNXTAFDLT-UHFFFAOYSA-L 0.000 claims 2
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims 2
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 2
- 229960002767 ethosuximide Drugs 0.000 claims 2
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229960002623 lacosamide Drugs 0.000 claims 2
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 2
- 229960001848 lamotrigine Drugs 0.000 claims 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims 2
- 229960001454 nitrazepam Drugs 0.000 claims 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 2
- 229960001233 pregabalin Drugs 0.000 claims 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 2
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims 2
- 229960002393 primidone Drugs 0.000 claims 2
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims 2
- 229960003014 rufinamide Drugs 0.000 claims 2
- 229940084026 sodium valproate Drugs 0.000 claims 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 2
- 229960001897 stiripentol Drugs 0.000 claims 2
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 claims 2
- 229960004394 topiramate Drugs 0.000 claims 2
- 229960002911 zonisamide Drugs 0.000 claims 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 1
- 241000004297 Draba Species 0.000 claims 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 claims 1
- 206010021750 Infantile Spasms Diseases 0.000 claims 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 201000006791 West syndrome Diseases 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 239000011247 coating layer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001582 fenfluramine Drugs 0.000 claims 1
- 201000011205 glycine encephalopathy Diseases 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000001617 migratory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022199076A JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553070P | 2017-08-31 | 2017-08-31 | |
| US62/553,070 | 2017-08-31 | ||
| PCT/JP2018/032949 WO2019045121A1 (en) | 2017-08-31 | 2018-08-30 | TREATMENT OF CNS DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199076A Division JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532508A JP2020532508A (ja) | 2020-11-12 |
| JP2020532508A5 true JP2020532508A5 (enExample) | 2021-09-30 |
| JP7196157B2 JP7196157B2 (ja) | 2022-12-26 |
Family
ID=63722720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511399A Active JP7196157B2 (ja) | 2017-08-31 | 2018-08-30 | Ｃｎｓ状態の治療 |
| JP2022199076A Active JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199076A Active JP7469445B2 (ja) | 2017-08-31 | 2022-12-14 | Ｃｎｓ状態の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11285139B2 (enExample) |
| EP (1) | EP3675852A1 (enExample) |
| JP (2) | JP7196157B2 (enExample) |
| KR (1) | KR102680786B1 (enExample) |
| CN (2) | CN111065394B (enExample) |
| MX (1) | MX2020001732A (enExample) |
| WO (1) | WO2019045121A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| CN111432812A (zh) | 2017-11-14 | 2020-07-17 | 爱思开生物制药株式会社 | 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途 |
| WO2020021372A1 (en) * | 2018-07-24 | 2020-01-30 | Zenvision Pharma Llp | Nasal drug delivery system of brivaracetam or salt thereof thereof |
| GB2580881A (en) * | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| CN114746408B (zh) * | 2019-12-02 | 2025-02-14 | 豪夫迈·罗氏有限公司 | 炔基-(杂芳基)-甲酰胺hcn1抑制剂 |
| GB2597312A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597311A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597285A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| US20240197704A1 (en) * | 2021-04-09 | 2024-06-20 | Johns Hopkins University | Treatment methods and compositions comprising perampanel |
| CN115487144A (zh) * | 2021-06-18 | 2022-12-20 | 北京万全德众医药生物技术有限公司 | 一种卢非酰胺的口服液制备方法 |
| WO2023175591A1 (en) * | 2022-03-18 | 2023-09-21 | Takeda Pharmaceutical Company Limited | Methods of treating neurological diseases |
| WO2024100531A1 (en) * | 2022-11-07 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Method of treating seizure disorders |
| WO2025126159A1 (en) * | 2023-12-15 | 2025-06-19 | Takeda Pharmaceutical Company Limited | A method for treating a neurological disease in a recreational drug user |
| WO2025257799A1 (en) * | 2024-06-14 | 2025-12-18 | Takeda Pharmaceutical Company Limited | Methods of treating dravet syndrome |
| CN121550436B (zh) * | 2026-01-23 | 2026-05-12 | 四川大学华西医院 | 组合物及联合用药方式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8648079B2 (en) | 2011-10-07 | 2014-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| EA029056B1 (ru) | 2012-12-11 | 2018-02-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
| WO2014163161A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6807322B2 (ja) | 2015-10-16 | 2021-01-06 | 武田薬品工業株式会社 | 複素環化合物の製造方法 |
-
2018
- 2018-08-30 US US16/642,153 patent/US11285139B2/en active Active
- 2018-08-30 MX MX2020001732A patent/MX2020001732A/es unknown
- 2018-08-30 EP EP18782213.5A patent/EP3675852A1/en active Pending
- 2018-08-30 CN CN201880055307.8A patent/CN111065394B/zh active Active
- 2018-08-30 CN CN202310328785.4A patent/CN116370475A/zh active Pending
- 2018-08-30 JP JP2020511399A patent/JP7196157B2/ja active Active
- 2018-08-30 WO PCT/JP2018/032949 patent/WO2019045121A1/en not_active Ceased
- 2018-08-30 KR KR1020207004753A patent/KR102680786B1/ko active Active
-
2022
- 2022-02-16 US US17/673,072 patent/US20220168294A1/en not_active Abandoned
- 2022-08-23 US US17/893,905 patent/US20230087903A1/en not_active Abandoned
- 2022-12-14 JP JP2022199076A patent/JP7469445B2/ja active Active
-
2024
- 2024-09-13 US US18/885,342 patent/US20250281477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Millea | N-acetylcysteine: multiple clinical applications | |
| ES2716906T3 (es) | Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab | |
| JP2016518387A5 (enExample) | ||
| Hu et al. | Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus | |
| JP2013505205A5 (enExample) | ||
| JP2013067645A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| JP2011511072A5 (enExample) | ||
| JP2010540616A5 (enExample) | ||
| JP2018513852A5 (enExample) | ||
| RU2008122358A (ru) | Лекарственные формы, содержащие ag013736 | |
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2012031131A5 (enExample) | ||
| JP2009529502A5 (enExample) | ||
| JP2019517469A5 (enExample) | ||
| JP2009543885A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2006513184A5 (enExample) | ||
| KR20140025314A (ko) | 복합 조성물 | |
| CN114224889A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2017531043A5 (enExample) | ||
| Rosenberg et al. | Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy | |
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении | |
| JP2012505830A5 (enExample) |